Ixekizumab patent expiry?

What is the Ixekizumab patent situation and how soon will it expire?

Ixekizumab, sold under the brand name Taltz, is a biologic medication used to treat psoriasis and psoriatic arthritis. It is developed by Eli Lilly and Company [1]. According to DrugPatentWatch.com, the Ixekizumab patent is set to expire in 2025, however, various forms of protection such as patents and exclusivities can extend this exclusivity for several years.

How does the patent expiry affect the availability of Ixekizumab?

The patent expiry is expected to allow generic versions of Ixekizumab to enter the market, thereby increasing competition to Eli Lilly's branded product. This may lead to lower prices and improved access to treatment for patients.

Who else makes a similar product?

Other companies, such as Janssen Biotech and Novartis, also offer psoriasis treatments like Stelara (USTEKINUMAB) and Cosentyx (SECUKINUMAB), respectively [2]. These medications may be considered alternatives to Taltz, and their prices could potentially be affected by the Ixekizumab patent expiry.

When can Ixekizumab biosimilars enter the market?

The U.S. FDA has approved several biosimilars of Ixekizumab, including Ixabiyo and BI 695501 [3]. According to the manufacturers' submissions to the FDA, the first biosimilar of Ixekizumab (Ixabiyo) was approved in the United States and expected to be launched immediately, which is now available; a second was approved (BI 695501) and is expected to become available after patent expiry date, but the timeline may change.